CSBTF (Kuros Biosciences) Common Stock: $4.1 Mil (As of Dec. 2025)


CSBTF Kuros Biosciences Ltd CSBTF
71 GF Score
Price $22.72
GF Value $54.72
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Common Stock?

Kuros Biosciences CSBTF 71 Common Stock is $4.1 Mil as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Kuros Biosciences's quarterly common stock declined from Dec. 2024 ($3.4 Mil) to Jun. 2025 ($3.1 Mil) but then increased from Jun. 2025 ($3.1 Mil) to Dec. 2025 ($4.1 Mil).

Kuros Biosciences's annual common stock declined from Dec. 2023 ($4.3 Mil) to Dec. 2024 ($3.4 Mil) but then increased from Dec. 2024 ($3.4 Mil) to Dec. 2025 ($4.1 Mil).

Kuros Biosciences Common Stock Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Common Stock Chart

Kuros Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.56 3.92 4.25 3.45 4.05

Kuros Biosciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 4.16 3.45 3.10 4.05
CSBTF
71GF Score
Kuros Biosciences Ltd CSBTF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $4.1 Mil mean?
Kuros Biosciences (CSBTF) has a Common Stock of $4.1 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kuros Biosciences and its competitors.
Is Kuros Biosciences' Common Stock too high?
Kuros Biosciences' current Common Stock is $4.1 Mil. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Common Stock compare to ABT and SYK?
Kuros Biosciences' Common Stock of $4.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Devices & Instruments company?
A good Common Stock depends on the Medical Devices & Instruments industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current Common Stock is $4.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Common Stock is $4.1 Mil. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Common Stock is $4.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Common Stock: $4.1 Mil
  • GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score

Get the complete analysis for CSBTF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.72
Price
$54.72
GF Value